Background and Purpose-Endothelial progenitor cells (EPCs) have been extensively investigated as a therapeutic approach for repairing the vascular system in cerebrovascular diseases. Beyond vascular regeneration per se, EPCs may also release factors that affect the entire neurovascular unit. Here, we aim to study the effects of the EPC secretome on oligovascular remodeling in a mouse model of white matter injury after prolonged cerebral hypoperfusion. Methods-The secretome of mouse EPCs was analyzed with a proteome array. In vitro, the effects of the EPC secretome and its factor angiogenin were assessed on primary oligodendrocyte precursor cells and mature human cerebral microvascular endothelial cells (hCMED/D3). In vivo, mice were subjected to permanent bilateral common carotid artery stenosis, then treated with EPC secretome at 24 hours and at 1 week, and cognitive outcome was evaluated with the Y maze test together with oligodendrocyte precursor cell proliferation/differentiation and vascular density in white matter at 4 weeks. Results-Multiple growth factors, cytokines, and proteases were identified in the EPC secretome, including angiogenin.
W hite matter damage caused by chronic cerebral hypoperfusion is a histological feature of stroke and cerebrovascular disease. Recently, it has been proposed that tissue physiopathology is influenced by the dynamic balance between deleterious versus beneficial responses to the initial insult, 1 including neuroinflammation, demyelination, and cell death but also regenerative capacities such as neurogenesis, angiogenesis, and neuroplasticity.
In the context of white matter remodeling, an endogenous pool of oligodendrocyte precursor cells (OPCs) is widely distributed in the adult brain for physiological myelin renewal and for repair under pathological conditions. 2 In demyelinating disorders, residual OPCs tend to proliferate and differentiate into oligodendrocytes to alleviate white matter damage. 3, 4 However, the regeneration of oligodendrocytes and myelin sheaths might fail because of an insufficient maturation of OPCs. Cell-based therapies are promising therapeutic options for enhancing oligodendrogenesis as bone marrow-derived mesenchymal stem cells and mononuclear cells have been reported to promote
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April 2018 myelin repair after intravenous injection into rodent models of demyelination. 5, 6 Also, the paracrine effects of transplanted mesenchymal stem cells have been reported to promote the OPC maturation and remyelination both in vitro and in vivo. 7, 8 Other studies have demonstrated that the administration of endothelial progenitor cells (EPCs) enhances neurogenesis and angiogenesis in mouse models of stroke, 9, 10 and EPC-secreted factors promoted cortical vascular remodeling after cerebral ischemia, 11 but its regenerative role in white matter damage is unknown. Among these secretome-remodeling factors, we have focused on angiogenin, a member of the Ribonuclease A superfamily which undergoes nuclear translocation in endothelial cells stimulating ribosomal RNA transcription, cell proliferation, and growth. 12, 13 With known effects on tumor neovascularization and cancer progression, 14, 15 it has been also described to promote hematopoietic regeneration of stem/progenitor cells, 16 being neurotropic and neuroprotective. 13 In this regard, mutations in angiogenin have been described in patients with familial and sporadic amyotrophic lateral sclerosis, affecting neuronal survival. 13 In the present study, we used a combination of in vitro culture systems and in vivo mouse model 17 to ask whether EPC-secreted factors (the EPC secretome) can enhance oligovascular proliferation, maturation, and repair in damaged white matter. Our results demonstrate for the first time that the treatment with the EPC secretome preserves cognitive function and enhances oligo-angiogenesis in the injured white matter.
Materials and Methods

Ethics Statement
Experiments were performed following institutionally approved protocols in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the Directives of the European Union. The article adheres the Transparency and Openness Promotion Guidelines, and all data supporting the findings of this study are available from the corresponding authors on reasonable request.
Cerebral Prolonged Hypoperfusion Model
Cerebral prolonged hypoperfusion was induced by bilateral common carotid artery stenosis using a microcoil in 24 male C57Bl/6 mice (2-3 months old, Charles River Institute) as described. 17 Follow-up for surgeries was performed by an investigator blinded for treatment. The mice were euthanized 28 days after the surgery; see the onlineonly Data Supplement.
Protocol for Conditioned Media Production
Mouse EPC cultures were used for the production of conditioned media (CM) in culture for 24 hours in endothelial basal media (CC-3156 from Lonza) as described 11 and filtered and concentrated using 10 KDa-membrane centrifuge tubes (Sartorius, V0601). Filtered and concentrated fresh endothelial basal media was used as vehicle treatment. See the online-only Data Supplement.
Secretome Therapy
Under anesthesia (1.5% isoflurane in 70% N 2 O and 30% O 2 ), each animal received 160 μL of CM or vehicle intravenously (retroorbital) at 24 hours and at 7 days after bilateral common carotid artery stenosis procedure.
5-Bromodeoxyuridine Labeling
A cell proliferation marker 5-bromodeoxyuridine (Sigma-Aldrich) was dissolved in 0.9% saline (5 mg/mL) and injected intraperitoneally (50 mg/kg body weight) every 12 hours between day 5 and 14 after the bilateral common carotid artery stenosis surgery.
Y Maze Test
The Y maze test was performed 28 days after the surgery as described. 18, 19 Memory and spontaneous activity indicators were evaluated blindly to treatment; see the online-only Data Supplement.
Isolation of Corpus Callosum and Western Blot
Nine anesthetized mice were transcardially perfused with ice-cold PBS. Brains were removed, and one half was placed in a brain tissue matrix and sectioned to obtain three 1-mm-thick coronal blocks. The corpus callosum was separated from the other half under a microsope as shown in Figure I in the online-only Data Supplement, frozen in dry ice, and stored at −80°C. For Western blot, lysates from the corpus callosum region were ultrasonically homogenized in 100 to 200 μL PRO-PREP Protein Extraction Kit (iNtRON Biotechnology). Samples were tested for anti-platelet-derived growth factor receptor-alpha (PDGFR-α), anti-CD31, MBP (myelin basic protein), or anti-β-actin as described in the online-only Data Supplement.
Immunohistochemistry
Mice were perfused with 4% paraformaldehyde in PBS, and the brain was postfixed for 24 hours in 4% paraformaldehyde in PBS at 4°C before cryoprotection with 30% sucrose. Frozen brains were cut into 16-μm-thick consecutive coronal sections at 0 to 0.5 mm anterior from the bregma and stained with anti-5-bromodeoxyuridine, anti-CD31 (for endothelial cells), anti-glutathione-S-transferase-pi (for mature oligodendrocytes), or anti-PDGFR-α (for oligodendrocyte progenitors) as detailed in the online-only Data Supplement.
Protein Profile of EPCs Secretome
CM were collected as described, and total protein content measured by the Comassie Protein Assay kit (Thermo Scientific). The protein profile (n=4) was analyzed using the Proteome Profiler Mouse Angiogenesis Array kit (R&D Systems); see the online-only Data Supplement.
Endothelial Cell Proliferation Assay
To test the angiogenic properties of CM on human cerebral microvascular endothelial cells, we assessed cell proliferation after treatment with CM or angiogenin (a potent proangiogenic factor identified in EPCs secretome) combined with Neomycin (an angiogenin inhibitor) with the Muse™ Cell Analyzer and the Cell Count and Viability Kit, as described.
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Endothelial Cell Viability Assay
Measurement of the reduction of 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide by human cerebral microvascular endothelial cells (hCMEC/D3) treated with Neomycin at different doses was performed as described in the online-only Data Supplement.
OPC Culture
Primary cultured rat OPCs were prepared according to our previous report 21 from cerebral cortices of 1-to 2-day-old SD rat pups; see the online-only Data Supplement.
OPC Viability Assay
OPC viability was assessed by WST reduction assay (Cell Counting Kit-8, Dojindo), which is similar to 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide assay. The cells were incubated with 10% WST solution for 1 hour at 37°C when the absorbance of the culture medium was measured at 450 nm wavelength with a reference wavelength of 630 nm.
Evaluation of OPC Differentiation
After OPCs were treated with EPC-CM or vehicle diluted from 1/5 to 1/50 in OPC differentiation media (final concentration of CNTF [ciliary neurotrophic factor], triiodothyronine, and B27 was 10 ng/ mL, 15 nmol/L, and 2%, respectively) for 24 hours, they were further cultured with the same OPC differentiation media for another 5 days.
Immunocytochemistry
Cultured EPCs or OPCs were immunostained for MBP or angiogenin, respectively, following standard procedures detailed in the online-only Data Supplement.
EPC-CM Western Blot for Angiogenin
Thirty-two microliter of reduced EPC-CM and endothelial basal media-vehicle were loaded in SDS-PAGE (12%) together with mouse recombinant angiogenin as positive control and transferred into polyvinylidene fluoride membranes as detailed in the online-only Data Supplement.
Statistical Analyses
Normality was assessed by the Shapiro-Wilk test. To assess differences between groups, t tests and one-way analysis of variance followed by Dunnett (bilateral) post hoc tests were used for normally distributed variables, while the Kruskal-Wallis and Mann-Whitney U tests were used to explore differences in non-normally distributed variables. Values are expressed and represented as mean±SD, and statistical analysis was conducted by the SPSS 15.0 software. A P value <0.05 was considered statistically significant.
Results
EPC Secretome Induced Endothelial and OPC Proliferation and Oligodendrocyte Maturation In Vitro
Mature endothelial cells and OPCs were cultured and exposed to EPC-CM or corresponding vehicle. Our results show that EPC-CM enhanced cell proliferation after treatment in both endothelial and OPC cells (P<0.05; Figure 1A and 1B). Additionally, EPC-CM-treated OPCs showed an increase in MBP expression (P<0.05; Figure 1C ), indicating the switch to a more mature oligodendrocyte phenotype.
EPC Secretome Proteomic Profile
A proteome array identified 38 proteins, including angiogenin and other promoters of angiogenesis (SDF-1 [stromal derived factor-1], PDGFAA/AB/BB [platelet-derived growth factor], VEGF-B [vascular endothelial growth factor], or several MMP [matrix metalloproteinase]), but also some inhibitors (endostatin or thrombospondin-2); see Table  I and Figure II in the online-only Data Supplement. At the same time, molecules critically involved in the proliferation, maturation, and survival of OPCs, such as PDGF, IGF-1 (insulin-like growth factor-1), EGF (epidermal growth factor), or IL-1β (interleukin-1β) were also detected in the EPC secretome.
Secreted Angiogenin as a Key Factor in the EPC Secretome
Western blots demonstrated that angiogenin was present in the EPC-CM (Figure 2A ). Immunocytochemistry confirmed that EPCs were indeed positive for angiogenin ( Figure 2B) .
In parallel, cell cultures treated with recombinant angiogenin at different doses confirmed the induction on endothelial proliferation (P<0.05) but not on OPC cells at the same doses ( Figure 3A and 3B) , respectively. Functional assays showed that the effects of the EPC secretome on endothelial proliferation were blocked by the addition of neomycin (10 μmol/L), an aminoglycoside antibiotic which blocks angiogenin signaling by inhibiting its nuclear translocation for angiogenesis (P<0.05); however, these effects were not observed in OPC cultures as expected ( Figure 3A and 3B) . No toxic effects of 
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neomycin were observed in endothelial cells (see Figure III in the online-only Data Supplement).
EPC Secretome Therapy Improved Cognitive Function In Vivo
Finally, we asked whether these oligovascular effects of the EPC secretome could be observed in vivo ( Figure 4A ). Mice were subjected to prolonged cerebral hypoperfusion via permanent bilateral occlusion of the carotid arteries. Figure 4B ). On the other hand, spontaneous activity, shown by the number of total arm entries, was not significantly different ( Figure 4B ).
Secretome Therapy Facilitated Oligovascular Remodeling in the White Matter
We next asked whether these beneficial effects of EPC-CM were associated with white matter remodeling in vivo. Vascular density in the corpus callosum area increased in those mice treated with EPCs-CM (P<0.05; Figure 5A ), whereas Western blot analysis showed some nonsignificant increase in CD31 expression (P<0.1; Figure 5B) . Similarly, the presence of OPCs (PDGFR-α marker) was not different between treatments ( Figure 5C ) when analyzed by Western blot, but the amount of MBP in those areas was significantly increased (by 97%) after EPC-CM treatment; P<0.05; Figure 5D . We then identified OPC proliferation/maturation since the number of total proliferating oligodendrocyte lineage cells increased by 32% in the damaged corpus callosum in mice receiving EPCs-CM (P<0.05; Figure 6A ). Of these, the number of proliferating OPCs (5-bromodeoxyuridine/PDGFR-a double-positive cells) was not different ( Figure 6B ), but there was a significant increase in the number of newly generated oligodendrocytes (5-bromodeoxyuridine/glutathione-S-transferase-pi double-positive cells) in EPC-CM-treated mice (P<0.05; Figure 6C ), representing ≈78% increase. These results suggest that EPC secretome therapy facilitated oligovascular remodeling and maturation of newly generated OPCs after prolonged cerebral hypoperfusion.
Discussion
The failure of the myelination/remyelination process attributed to insufficient regenerative responses, as well as the suppression of oligodendrocyte maturation, accompanies white mater injury in stroke and cerebrovascular disease. Hence, treatments boosting endogenous myelin repairing responses would be effective to improve patients' outcome. Our findings in the present study support the therapeutic actions of factors secreted by EPCs, highlighting the importance of angiogenin, a known enhancer for angiogenesis. We finally demonstrate the regenerative actions of the EPC secretome in vascular and myelin remodeling in an experimental mouse model of white matter injury.
Cell transplantation is considered a valid therapeutic strategy to repair the injured tissue. 22 In this regard, several types 
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of stem and progenitor cells have been successfully tested in preclinical models of stroke, multiple sclerosis, or neurodegenerative diseases. 23 However, the mechanisms of repair are still under investigation, including direct cell replacement, indirect secretion of nourishing factors, or the creation of a biobridge that connects the neurogenic sites of the brain with the injured areas with active remodeling. 24, 25 EPCs are bone marrow-derived cells capable of differentiating ex vivo into endothelial-phenotyped cells representing a model for endothelial generation and vascular repair. 26, 27 Other studies have demonstrated the benefit of factors secreted by progenitor/stem cells, such as VEGF 28 or hepatocyte growth factor 8 or IL (interleukin)-8. 29 In this context, the secretome of EPCs is known to stimulate endothelial cell migration, growth, and function 30, 31 and to protect from axonal degeneration in cultured cortical neurons exposed to oxygen-glucose deprivation. 32 In this regard, intravenously administered EPC-CM enhances vascular remodeling in a cortical model of stroke, 11 whereas intramuscular injections of similar products promoted tissue revascularization and recovery in a model of hindlimb ischemia. 33 After white matter injury, Bai et al 8 have recently shown that CM obtained from mesenchymal stem cells is a valid therapeutic strategy to reverse the effects of inflammatory demyelinating diseases such as experimental autoimmune encephalomyelitis, a model of multiple sclerosis. The authors show that the effects of mesenchymal stem cells-CM are dependent on the presence of hepatocyte growth factor, accelerating remyelination, and functional recovery. To our knowledge, the present study is the first describing recovery from white matter injury after the administration of an EPC secretome in a cell-free approach.
The prolonged hypoperfusion model used in this study causes subcortical white matter injury affecting oligodendrocyte/myelin integrity, without apparent neuronal loss at 1 month. 17, 19, 34, 35 Our study demonstrates for the first time the interaction of the EPC secretome with vascular and myelin remodeling by increasing vessel density, the number of proliferating oligodendrocyte lineage cells, and enhancing myelination in the corpus callosum. EPCs can be incorporated into neovessels, 26, 36 and their restorative actions on vascular remodeling have been widely reported in vivo in stroke models [37] [38] [39] or traumatic brain injury. 40 At the same time, several nourishing factors have been reported to modulate EPCs function. For example, VEGF-C regulates the proliferation of neural progenitors expressing VEGFR-3 41 and stimulates the proliferation of EPCs in a hypoxia-ischemia in vivo model, 42 whereas VEGF-A strongly promotes OPC migration in a concentration-dependent manner, in vitro. 43 We have identified the presence of several trophic, proteolytic, and signaling factors in the EPC-CM that support the therapeutic effects on white matter remodeling reported in this study. It is known that SDF1, VEGF, or MMPs could be responsible for maintaining the oligovascular niche in the normal and injured brain 44 and that hepatocyte growth factor is essential to accelerate remyelination and recovery in the experimental autoimmune encephalomyelitis model. 8 We have shown that several of these factors, among others, are present in our therapeutic EPC-CM. The relative contribution of each factor on oligovascular remodeling is unknown, but we pursue on exploring the role of angiogenin as a potent proangiogenic molecule that enhances endothelial angiogenesis, 12 which can be pharmacologically inhibited by antibiotics such as neomycin or neamine. 45, 46 In this regard, we observe that brain endothelial cells proliferated with EPCs secretome treatment being reverted in the presence of neomycin, highlighting the angiogenin-dependent effects of secretome therapy in vascular remodeling. However, we acknowledge that our model systems cannot directly link angiogenin actions in the remodeling brain, especially on oligodendrocyte proliferation, and that other nourishing factors present in the EPCs secretome could be also contributing to the observed white matter repair. Nevertheless, others have suggested that angiogenin may have potent nonvascular effects such as neuroprotection against oxidative stress 47 or hypoxic injury. 48 Importantly, we explore the cognitive function at the end of the study period when spatial working memory dysfunction has been observed, 19, 49 allowing the evaluation of any therapeutic intervention. Our results show that the treatment with EPC-CM improves the functional outcome of mice exposed to cerebral hypoperfusion using the Y maze test. Moreover, the scores obtained for alternation rates by EPC-CM-treated mice were similar to those scored by sham-operated mice in other studies of the group. 18 This finding seems to be selective for the cognitive function and not for motor function. The longterm cognitive status and the effect of prolonged treatments with EPCs secretome deserves to be further evaluated.
Summary
Treatment with the EPC secretome in a mouse model of prolonged cerebral hypoperfusion may improve cognitive function by enhancing oligovascular repair in white matter. These results highlight the importance of EPC-released proteins such as angiogenin in therapeutic strategies for white matter injury after cerebrovascular disease.
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